Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir kamagra Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

Tu1010 dabur 090810

DABUR INDIA LIMITED
RESEARCH
EQUITY RESEARCH
August 10, 2009
RESULTS REVIEW
Dabur India Limited
Share Data
Dismal monsoon to play spoilsport in near-term
For Q1’10, Dabur India Ltd (Dabur) posted a healthy top-line growth of 23% yoy to Rs. 7.4 bn led by robust 16% yoy growth in volumes across its key categories. EBITDA grew by 30.3% yoy to Rs. 1.3 bn and margins by 93 bps to 16.5% due to softening of raw material prices. We believe Dabur will witness robust revenue growth in medium-to-long term on the back of increasing traction in its portfolio mix and entry into new geographies. However, owing to the weak near-term outlook due to dismal monsoon, and Valuation Ratios (Consolidated)
recent run-up in the stock prices, we maintain our hold rating on the stock. Year to 31 March
Healthy double-digit volume growth to continue: The Government’s
stimulus to rural employment, through increased fund allocation to various rural development schemes, would augment the rural demand. We believe Dabur would be a large beneficiary of this as it garners around 50% of the Shareholding Pattern (%)
revenue from rural India through its wide distribution network. Furthermore, we expect Dabur to gain more traction in its international markets as well as in the new geographies as its products have received astonishing response in these markets. Post the Fem Care acquisition, Dabur is also looking for Relative Performance
overseas acquisition opportunities to add more established brands to its portfolio to accelerate its revenue growth. However, we expect weak monsoon will restrict the domestic growth in the near-term. Factoring all the above, we expect the revenue to grow at a CAGR of 19.3% for FY09–11E. Margins to contract in near term: We have cut our EBITDA margin
estimates for the second half of FY10 by ~150 bps due to increase in input cost following weak monsoon and increase in ad spendings primarily related Rebased BSE Index
to Fem Care branding. However, we maintain margins for FY11 at 18%. Key Figures (Consolidated)
Quarterly Data
(Figures in Rs. mn, except per share data) Net Sales Margins(%)
Per Share Data (Rs.)
Please see the end of the report for disclaimer and disclosures.
-1-
DABUR INDIA LIMITED
RESEARCH
EQUITY RESEARCH
August 10, 2009
Valuation
We have raised our target price from Rs. 116 to Rs. 141, due to strong revenue visibility in medium-to-long term from the rural India and international markets. Besides, the Company has cash balance of around 1.4 bn and has a healthy debt to equity ratio of 0.28x, which will help it to meet its future plan to grow inorganically. At the CMP the stock trades at a forward P/E of 25x and 21x for FY10E and FY11E. Based on our DCF valuation (assuming a WACC of 12.2%, Rf of 7.88%, and terminal growth of 5%) we arrived at a target price of Rs. 141, which provides an upside of 8% over the CMP of Rs. 130.45. Hence, we maintain a neutral view on the stock. Cost of Capital
Result Highlights
Dabur reported an outstanding revenue growth of 23% yoy to Rs. 7.4 bn, in Q1’10, on the back of robust volume growth and better pricing of 16% and 3.5%, respectively. Balance 2.7% growth came from translation gains in international business. Moreover, the Company, after completing take-over formalities of Fem care on June 25th, consolidated the latter’s results for six days of the quarter, which contributed 0.6% yoy to the total growth. EBITDA margin improved 93 bps yoy to 16.5% because of decline in raw material cost and savings in fixed and variable overheads, partially mitigating the adverse impact of the increase in the advertisement and publicity expenditure. Adjusted net profit grew 29% yoy to Rs. 913.91 mn Please see the end of the report for disclaimer and disclosures.
-2-
DABUR INDIA LIMITED
RESEARCH
EQUITY RESEARCH
August 10, 2009
Segmental Highlights and Outlook
Consumer Care Division (CCD) grew by 20.2% yoy to Rs. 5.64 bn and
remained the key revenue driver contributing 75% to the total revenue. Like previous quarter, Hair Care, Shampoo, and Baby & Skin care led the growth. Hair care leapt 22.5% yoy on the back of 15.8% growth in the Hair Oil category especially, Anmol Coconut oil and Vatika Hair oil which grew 42.7% and 15.5%, respectively. Shampoo category performed well led by 48.6% yoy growth in Vatika shampoos. Sequentially, Dabur brands have gained further market share in the normal shampoo category from 6.8% in Q4’09 to 7.3% in Q1’10. In Baby Skin Care, Gulabari grew 47.2%, whereas Dabur Lal Tail has been re-launched with new proposition. Food Division’s revenue grew by 21.6% in Q1’10 as compared with 15.4% growth in Q1’09 owing to 17.7% growth in Real franchise expanding the sales channels for EBITDA Margin
We expect CCD division to grow by 20% yoy for FY10 driven by strong traction in key categories like hair-care, oral care, and juices aided by launches of new products and variants. Also nearly 4% yoy growth is expected from Fem Care Pharma from next quarter. Consumer Health Division (CHD) grew by 12.5% yoy, driven by the
popular brands - Pudin Hara, Churnas, and Asavs. The OTC portfolio grew by 15% yoy and the ethical portfolio by a mere 8%. The transfer of some products (Pudin hara, Janam Ghunti, Hingoli, Sat Isabgol and Gripe Water) to its CHD division from CCD has shown positive outcomes, resulting in better volume growth. We do not expect this division to significantly contribute to overall growth in the absence of any new launches. International Business grew by a whooping 52.9% yoy during the quarter
on the back of robust performances in key geographies like GCC, Egypt, Dabur is expanding aggressively
Levant, and North African markets. Part of it is on account of translational into newer geographies
gains, excluding that the growth was 35%. New products (Dermoviva soap and Amla Hair Cream) launched in the previous quarters have contributed Please see the end of the report for disclaimer and disclosures.
-3-
DABUR INDIA LIMITED
RESEARCH
EQUITY RESEARCH
August 10, 2009
We expect Dabur brands to continue to gain traction in its overseas markets as a lot of opportunities are still there in terms of volume and pricing. Moreover, with inclusion of Uzbekistan, Guinea, and Belarus in the current quarter, the Company is expanding its presence into new geographies which would accelerate revenue growth in international business. Key Risks
The worse-than-expected impact of monsoons on the rural demand is a key Key Figures (Consolidated)
Year to March
(Figures in Rs. mn, except per share data) Margins(%)
Per Share Data (Rs.)
Please see the end of the report for disclaimer and disclosures.
-4-
DABUR INDIA LIMITED
RESEARCH
EQUITY RESEARCH
August 10, 2009

Disclaimer

This report is not for public distribution and is only for private circulation and use. The Report should not be reproduced
or redistributed to any other person or person(s) in any form. No action is solicited on the basis of the contents of this
report.
This material is for the general information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be considered as an offer to sell or the solicitation of an offer to buy any stock or derivative in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Indiabulls Securities Limited. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. You are advised to independently evaluate the investments and strategies discussed herein and also seek the advice of your financial adviser. Past performance is not a guide for future performance. The value of, and income from investments may vary because of changes in the macro and micro economic conditions. Past performance is not necessarily a guide to future performance. This report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Any opinions expressed here in reflect judgments at this date and are subject to change without notice. Indiabulls Securities Limited (ISL) and any/all of its group companies or directors or employees reserves its right to suspend the publication of this Report and are not under any obligation to tell you when opinions or information in this report change. In addition, ISL has no obligation to continue to publish reports on all the stocks currently under its coverage or to notify you in the event it terminates its coverage. Neither Indiabulls Securities Limited nor any of its affiliates, associates, directors or employees shall in any way be responsible for any loss or damage that may arise to any person from any error in the information contained in this report. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject stock and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without Indiabulls Securities Limited prior written consent. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Indiabulls Securities Limited recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Indiabulls Securities Limited shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of National Stock Exchange or Bombay Stock Exchange. Indiabulls (H.O.), Plot No- 448-451, Udyog Vihar, Phase - V, Gurgao n - 122 001, Haryana. Ph: (0124) 3989555, 3989666 -5-

Source: http://www.livemint.com/r/LiveMint/Period1/oldpdf/f6fcc47a-97a3-4227-983d-4e68746dd18d.pdf

Untitled

MANAGER’S DISCUSSION AND ANALYSIS OF FUTURE OPERATIONS Since the Manager will manage the Properties differently from the manner in which the RCOperations have historically been managed, the Audited Financial Statements of the RCOperations set forth in Appendix I to this Offering Circular and related discussions and informationin respect of the RC Operations contained in the section headed

soinspalliatifs.hug-ge.ch

Liste et utilisation des médicaments de la mallette d’urgence pour les patients en soins palliatifs (par ordre alphabétique)§ Buscopan® (Scopolamine butylbromide) ampoule 20 mg Indication : douleur spasmodique, iléus Voie d’administration : sc, im, iv, peut être administré en iv direct, compatible avec du NaCl 0.9% Posologie habituelle : 20 mg 3-4x/j, maximum 120 mg/j

Copyright © 2010-2014 Internet pdf articles